Lipid Nanoparticulate Drug Delivery And Nanomedicine

Lipids in Nanotechnology

Volumn , Issue , 2012, Pages 221-268

  Mansour, Heidi M ^a   Rhee, Yun Seok ^b   Park, Chun Woong ^a   DeLuca, Patrick P ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Gyeongsang National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84863488316     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-9818936-7-9.50012-3     Document Type: Chapter

References (363)

1. Abra R.M., et al. The next generation of liposome delivery systems: recent experience with tumor-targeted, stericallystabilized immunoliposomes and active-loading gradients. J. Liposome Res. 2002, 12:1-3.
2. Aji Alex M.R., Chacko A.J., et al. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur. J. Pharm. Sci. 2010, 42:11-18.
3. Akwete L.A., Hsu L. Leuprolide and Other LH-RH Analogues. In Stability and Characterization of Protein and Peptide Drugs: Case Histories 1993, 159-199. Plenum Press:, New York.
4. Alghadyan A.A., Peyman G.A., Khoobehi B., et al. Liposomebound cyclosporine: retinal toxicity after intravitreal injection. Int. Ophthalmol. 1988, 12:105-107.
5. Alghadyan A.A., Peyman G.A., Khoobehi B., et al. Liposomebound cyclosporine: clearance after intravitreal injection. Int. Ophthalmol. 1988, 12:109-112.
6. Amselem S., Gabizon A., Barenholz Y. A large-scale method for the preparation of sterile and non pyrogenic liposomal formulations of defined size distributions for clinical use. In Liposome Technology 2nd Edition. 1993, 501-525. CRC Press:, Boca Raton, FL. G. Gregoriadis (Ed.).
7. Angelucci, D. New Solutions for Dry Eye, EyeWorld online, 2001 (Internet) . http://eyeworld.org.pastissue.php.
8. Antimisiaris S.G., Kallinteri P., Fatouros D.G. Liposome and drug delivery. Pharmaceutical Manufacturing Handbook. 2008, 10:443-534. John Wiley & Sons:, Hobokin, New Jersey.
9. Aquilano D., Cavalli R., et al. Solid lipospheres obtained from hot microemulsions in the presence of different concentrations of cosurfactant: the crystallization of stearic acid polymorphs. Thermochim. Acta 1993, 230:29-37.
10. Arien A., Goigoux C., Baquey C., Dupuy B. Study of in vitro and in vivo stability of liposomes loaded with calcitonin or indium in the gastrointestinal tract. Life Sci. 1993, 53:1279-1290.
11. Artman C., Roding J., Ghyczy M., Prazel H.G. Liposomes from soya phospholipids as percutaneous drug carriers: qualitative in vivo investigations with antibody-loaded liposomes. Arzneium. Forsch Drug Res. 1990, 40(II):1363-1365.
12. Artman C., Roding J., Ghyczy M., Prazel H.G. Liposomes from soya phospholipids as percutaneous drug carriers: quantitative in vivo investigations with radioactivity labelled liposomes. Arzneium. Forsch Drug Res. 1990, 40(II):1365-1368.
13. Assil K.K., Frucht-Perry J., Ziegler E., et al. Tobramycin liposomes. Single subconjunctival therapy of pseudomonal keratitis. Invest. Ophthalmol. Vis. Sci. 1991, 32:16-20.
14. Attama A.A., Reichl S., et al. Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int. J. Pharm. 2008, 355:307-313.
15. Attama A.A., Reichl S., et al. Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea. Curr. Eye Res. 2009, 34:698-705.
16. Averina E.S., Seewald G., et al. Nanostructured lipid carriers (NLC) on the basis of Siberian pine (Pinus sibirica) seed oil. Pharmazie 2010, 65:25-31.
17. Bakker-Woudenberg I.A. Long-circulating sterically stabilized liposomes as carriers of agents for treatment of infection or for imaging infectious foci. Int. J. Antimicrob. Agents 2002, 19:299-311.
18. Balazs D.A., Godbey W.T. Liposomes for use in gene delivery. J. Drug Del. 2011, 326497:1-12.
19. Banerjee R. Liposomes: applications in medicine. J. Biomater. 2001, 114:3-21.
20. Bangham A.D., Standish M.M., Watkins J.C. Diffusion of univalent ion across the lamellae of swollen phospholipids. J. Mol. Bio. 1965, 13:238-252.
21. Barenholzt Y., Amselem S., Litchtenberg D. A new method for preparation of phospholipid vesicles (liposomes)-french press. FEBS Letters 1979, 99:210-214.
22. Barenholz Y., Crommelin D.J.A. Encyclopedia of Pharmaceutical technology 1994, 1-39. Marcel Dekker:, New York.
23. Barza M., Baum J., Szoka F. Jr. Pharmacokinetics of subconjunctival liposome-encapsulated gentamicin in normal rabbit eyes. Invest. Ophthalmol. Vis. Sci. 1984, 25:486-490.
24. Basaran E., Demirel M., et al. Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J. Microencapsul. 2010, 27:37-47.
25. Bates S., Zografi G., Engers D., Morris K., Crowley K., Newman A. Analysis of amorphous and nanocrystalline solids from their X-ray diffraction patterns. Pharm. Res. 2006, 23:2333-2349.
26. Battaglia L., Gallarate M., et al. Solid lipid nanoparticles produced through a coacervation method. J. Microencapsul. 2010, 27:78-85.
27. Behr J.P. Gene transfer with synthetic cationic amphiphiles: prospects for gene therapy. Bioconjugate Chem. 1994, 5:382-389.
28. Behr J.P., Demeneix B., Loeffler J.P., Perez-Mutul J. Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA. Proceedings of the National Academy of Sciences of the United States of America 1989, 86:6982-6986.
29. Betagiri J.V., Jenkins S.A., Parsons D.L. Liposomes drug delivery system. 1993, 120. Technomic Publishing:, Lanchaster, Basel, Switzerland.
30. Bhalekar M.R., Pokharkar V., et al. Preparation and evaluation of miconazole nitrate-loaded solid lipid nanoparticles for topical delivery. AAPS PharmSciTech 2009, 10:289-296.
31. Bi R., Shao W., Wang Q., Zhang N. Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery. J. Drug Target 2008, 16:639-648.
32. Blasi P., Giovagnoli S., et al. Solid lipid nanoparticles for targeted brain drug delivery. Adv. Drug Deliv. Rev. 2007, 59:454-477.
33. Blume G., Cevc G. Molecular mechanism of the lipid vesicle longevity in vivo. Biochim. Biophys. Acta 1993, 1146:157-168.
34. Blume G., et al. Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of polymeric chains combines effective target binding with long circulation times. Biochim. Biophys. Acta 1993, 1149:180-184.
35. Bondi M.L., Craparo E.F. Solid lipid nanoparticles for applications in gene therapy: a review of the state of the art. Expert Opin. Drug Deliv. 2010, 7:7-18.
36. Bondi M.L., Fontana G., et al. Preparation and characterization of solid lipid nanoparticles containing cloricromene. Drug Deliv. 2003, 10:245-250.
37. Brandl M. Liposomes as drug carriers: a technological approach. Biotech. Ann. Rev. 2001, 7:59-85.
38. Brandl M., Bachmann D., Drechsler D., Bauer K.H. Lipopsome preparation by a new high pressure homogenizer Gaulin Micron LAB 40. Drug Dev. Ind. Pharm. 1990, 16:2167-2191.
39. Brioschi A., Zara G.P., et al. Cholesterylbutyrate solid lipid nanoparticles as a butyric acid prodrug. Molecules 2008, 13:230-254.
40. Budker V., Gurevich V., Hagstrom J.E., et al. pH-sensitive, cationic liposomes: a new synthetic virus-like vector. Nature Biotech. 1996, 14:760-764.
41. Bunker M., Davies M., Roberts C. Towards screening of inhalation formulations: measuring interactions with atomic force microscopy. Expert Opin. Drug Deliv. 2005, 2:613-624.
42. Burgess D.J., Crommelin D.J.A., Hussain A.S., Chen M.-L. Assuring quality and performance of sustained and controlled release parenterals: EUFEPS workshop report. Eur. J. Pharm. Sci. 2004, 21:769-790.
43. Caliph S.M., Charman W.N., et al. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J. Pharm. Sci. 2000, 89:1073-1084.
44. Campos S., Shapiro C.L. Chapter 15. Clinical evaluation of liposomal anthracyclines, Liposomes-Rational Design. 1999, 363-377. Marcel Dekker:, New York.
45. Castro G.A., Orefice R.L., et al. Development of a new solid lipid nanoparticle formulation containing retinoic acid for topical treatment of acne. J. Microencapsul. 2007, 24:395-407.
46. Cattel L., Ceruti M., Dosio F. From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Tumori. 2003, 89:237-249.
47. Cavalli R., Morel S., et al. Preparation and evaluation in vitro of colloidal lipospheres containing pilocarpine as ion pair. Int. J. Pharm. 1995, 117:243-246.
48. Cavalli R., Caputo O., et al. Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int. J. Pharm. 1997, 148:47-54.
49. Cavalli R., Gasco M.R., et al. Evaporative drying of aqueous dispersions of solid lipid nanoparticles. Drug Dev. Ind. Pharm. 2001, 27:919-924.
50. Cavalli R., Gasco M.R., et al. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int. J. Pharm. 2002, 238:241-245.
51. Cevc G., Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim. Biophys. Acta 1992, 1104:226-232.
52. Cevc G., Schatzlein A., Blume G. Transdermal drug carriers: basic properties, optimization and transfer efficiency in the case of epicutaneously applied peptides. J. Control Rel. 1995, 36:3-16.
53. Cevc G., Blume G., Schatzlein A., et al. The skin: a pathway for systemic treatment with patches and lipid-based agent carriers. Adv. Drug Deliv. Rev. 1996, 18:349-378.
54. Changsan N., Chan H.K., Separovic F., Srichana T. Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation. J. Pharm. Sci. 2009, 98:628-639.
55. Charcosset C., El-Harati A., et al. Preparation of solid lipid nanoparticles using a membrane contactor. J. Control Rel. 2005, 108:112-120.
56. Chattopadhyay P., Huff R., Shekunov B.Y. Drug encapsulation using supercritical fluid extraction of emulsions. J. Pharm. Sci. 2006, 95:667-679.
57. Chattopadhyay P., Shekunov B.Y., et al. Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Adv. Drug Deliv. Rev. 2007, 59:444-453.
58. Chavanpatil M.D., Khdair A., et al. Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux. Mol. Pharm. 2007, 4:730-738.
59. Chen H., Torchilin V., Langer R. Lectin-bearing polymerized liposomes as potential oral vaccine carriers. Pharm. Res. 1996, 13:1378-1383.
60. Chen H., Chang X., et al. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J. Control Rel. 2006, 110:296-306.
61. Chen M.L. Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective. Adv. Drug Deliv. Rev. 2008, 60:768-777.
62. Choi S.H., Jin S.E., et al. Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells. Eur. J. Pharm. Biopharm. 2008, 68:545-554.
63. Choudhari K.B., Labhasetwar V., Dorle A.K. Liposomes as a carrier for oral administration of insulin: effect of formulation factors. J. Microencapsulation 1994, 11:319-325.
64. Chougule M., Padhi B., Misra A. Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics. Int. J. Nanomed. 2007, 2:675-688.
65. Clark M.A., Jepson M.A., et al. Exploiting M cells for drug and vaccine delivery. Adv. Drug Deliv. Rev. 2001, 50:81-106.
66. Courrier H.M., Butz N., Andamme F. Pulmonary drug delivery systems: developments and prospects. Crit. Rev. Ther. Drug Carrier Syst. 2002, 19:425-498.
67. Crommelin D.J., Storm G. Liposomes: from the bench to the bed. J. Liposome Res. 2003, 13:33-36.
68. Daemen T., et al. Opportunities in targeted drug delivery to Kupffer cells: delivery of immunomodulators to Kupffer cells-activation of tumoricidal properties. Adv. Drug Deliv. Rev. 1995, 17:21-30.
69. Deamer D., Bangham A.D. Large volume liposomes by an ether vaporization method. Biochim. Biophys. Acta 1976, 443:629-634.
70. DeCastro M., Saijoh Y., Schoenwolf G.C. Optimized cationic lipid-based gene delivery reagents for use in developing vertebrate embryos. Dev. Dynam. 2006, 235:2210-2219.
71. del Pozo-Rodriguez A., Delgado D., et al. Solid lipid nanoparticles: formulation factors affecting cell transfection capacity. Int. J. Pharm. 2007, 339:261-268.
72. del Pozo-Rodriguez A., Delgado D., et al. Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking in RPE cells. Int. J. Pharm. 2008, 360:177-183.
73. del Pozo-Rodriguez A., Pujals S., et al. A proline-rich peptide improves cell transfection of solid lipid nanoparticle-based non-viral vectors. J. Control Rel. 2009, 133:52-59.
74. Densmore C.L. Advances in noninvasive pulmonary gene therapy. Curr. Drug Deliv. 2006, 3:55-63.
75. Deshmukh D.D., Ravis W.R., Betageri G.V. Improved delivery of cromolyn from oral proliposomal beads. Int. J. Pharm. 2008, 358:128-136.
76. Dingler A., Blum R.P., et al. Solid lipid nanoparticles (SLN/Lipopearls)-a pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products. J. Microencapsul. 1999, 16:751-767.
77. Duddu S.P., Sisk S.A., Walter Y.H., et al. Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder. Pharm. Res. 2002, 19:689-695.
78. Dwivedi V., Vasco A., Vedi S., Dangi A., Arif K., Bhattacharya S.M., Owais M. Adjuvanticity and protective immunity of Plasmodium yoelii nigeriensis blood-stage soluble antigens encapsulated in fusogenic liposome. Vaccine 2009, 27:473-482.
79. Ebrahim S., Peyman G.A., Lee P.J. Applications of Liposomes in Ophthalmology. Surv. Ophthalmol 2005, 50:167-182.
80. El-Harati A.A., Charcosset C., et al. Influence of the formulation for solid lipid nanoparticles prepared with a membrane contactor. Pharm. Dev. Technol. 2006, 11:153-157.
81. Fang J.Y., Fang C.L., et al. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur. J. Pharm. Biopharm. 2008, 70:633-640.
82. Farhood H., Gao X., Son K. Cationic liposomes for direct gene transfer in therapy of cancer and other diseases. Anals New York Academy Sci. 1994, 716:23-35.
83. Farhood H., Serbina N., Huang L. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim. Biophys. Acta 1995, 1235:289-295.
84. Felgner P.L., Gadek T.R., Holm M., et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proceedings of the National Academy of Sciences of the United States of America 1987, 84:7413-7417.
85. Felgner P.L., Ringold G.M. Cationic liposome-mediated transfection. Nature 1989, 337:387-388.
86. Foldvari M. In vitro cutaneous and percutaneous delivery and in vivo efficacy of tetracaine from liposomal and conventional vehicles. Pharm. Res. 1994, 11:1593-1598.
87. Foldvari M., Gesztes A., Mezei M. Dermal drug delivery by liposome encapsulation: clinical and electron microscopic studies. J. Microencapsu. 1990, 7:479-489.
88. Fontana G., Maniscalco L., et al. Solid lipid nanoparticles containing tamoxifen characterization and in vitro antitumoral activity. Drug Deliv. 2005, 12:385-392.
89. Freitas C., Muller R.H. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur. J. Pharm. Biopharm. 1999, 47:125-132.
90. Freitas S., Merkle H.P., Gander B. Ultrasonic atomisation into reduced pressure atmosphere- envisaging aseptic spray-drying for microencapsulation. J. Control Rel. 2004, 95:185-195.
91. Frezard F. Liposomes: from biophysics to the design of peptide vaccines. Braz. J. Biol. Res. 1999, 32:181-189.
92. Frucht-Perry J., Assil K.K., Ziegler E., et al. Fibrin-enmeshed tobramycin liposomes: single application topical therapy of Pseudomonas keratitis. Cornea 1992, 11:393-397.
93. Fundaro A., Cavalli R., et al. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol. Res. 2000, 42:337-343.
94. Gabizon A. Emerging role of liposomal drug carrier systems in cancer chemotherapy. J. Liposome Res. 2003, 13:17-20.
95. Gabizon A., Barenholz Y. Liposomal Anthracyclines: From Basics to Clinical Approval of PEGylated Liposomal Doxorubicin. In Liposomes-Rational Design 1999, 343-362. Marcel Dekker:, New York, .
96. Gabizon A., Catane R., Uziely B., et al. Prolonged circulation tima and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994, 54:987-992.
97. Gallarate M., Trotta M., et al. Preparation of solid lipid nanoparticles from w/o/w emulsions: preliminary studies on insulin encapsulation. J. Microencapsul. 2009, 26:394-402.
98. Gao X., Huang L. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem. Biophys. Res. Comm. 1991, 179:280-285.
99. Gao X., Kim K.S., Liu D. Nonviral gene delivery: what we know and what is next. AAPS J. 2007, 9:92-104.
100. Garcia-Fuentes M., Torres D., et al. Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloids Surf. B-Biointer. 2002, 27:159-168.
101. Gershkovich P., Wasan K.M., Barta C.A. A review of the application of lipid-based systems in systemic, dermal/transdermal, and ocular drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 2008, 25:545-584.
102. Gesztes A., Mezei M. Topical anaesthesia of skin by liposome-encapsulated tetracaine. Anesth. Analg. 1988, 67:1079-1081.
103. Gilani K., Najafabadi A.R., Barghi M., Rafiee-Tehrani M. The effect of water to ethanol feed ratio on physical properties and aerosolization behavior of spray dried cromolyn sodium particles. J. Pharm. Sci. 2005, 94:1048-1059.
104. Gokce E.H., Sandri G., et al. Cyclosporine A-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release in rabbit eyes. Curr. Eye Res. 2009, 34:996-1003.
105. Goppert T.M., Muller R.H. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J. Drug Target 2005, 13:179-187.
106. Gregoriadis G. Overview of liposomes. J. Antimicrob. Chemother. 1991, 28(supp. B):39-48.
107. Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol. 1995, 13:527-537.
108. Gulbake A., Jain A., et al. Solid lipid nanoparticles bearing oxybenzone: in-vitro and in-vivo evaluation. J. Microencapsul. 2010, 27:226-233.
109. Gupta Y., Jain A., et al. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J. Pharm. Pharmacol. 2007, 59:935-940.
110. Hatziantoniou S., Deli G., et al. Scanning electron microscopy study on nanoemulsions and solid lipid nanoparticles containing high amounts of ceramides. Micron. 2007, 38:819-823.
111. Hickey A.J., Mansour H.M. Chapter 44: Formulation challenges of powders for the delivery of small molecular weight molecules as aerosols. Modified-Release Drug Delivery Technology Second Edition. 2008, 573-602. Informa Healthcare:, New York.
112. Hickey A.J., Mansour H.M. Chapter 5: Delivery of drugs by the pulmonary route. Modern Pharmaceutics Volume 2: Applications and Advances Fifth Edition. 2009, 191-219. Taylor & Francis, New York.
113. Hickey A.J., Mansour H.M., Telko M.J., et al. Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics. J. Pharm. Sci. 2007, 96:1282-1301.
114. Hiroshi Y., Shozo M., et al. Bifunctional delivery system for selective transfer of bleomycin into lymphatics via enteral route. Int. J. Pharm. 1981, 8:291-302.
115. Hong Y., Hu F.Q., et al. Effect of PEG2000 on drug delivery characterization from solid lipid nanoparticles. Pharmazie 2006, 61:312-315.
116. Hsu S.H., Wen C.J., et al. Physicochemical characterization and in vivo bioluminescence imaging of nanostructured lipid carriers for targeting the brain: apomorphine as a model drug. Nanotechnol. 2010, 21:405101.
117. Hu C., Rhodes D.G. Proniosomes: A novel drug carrier preparation. Int. J. Pharm. 1999, 185:23-35.
118. Hu F.Q., Yuan H., et al. Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int. J. Pharm. 2002, 239:121-128.
119. Hu F.Q., Hong Y., et al. Preparation and characterization of solid lipid nanoparticles containing peptide. Int. J. Pharm. 2004, 273:29-35.
120. Hu F.Q., Wu M., et al. A novel preparation of solid lipid nanoparticles with cyclosporin A for prolonged drug release. Pharmazie 2004, 59:683-685.
121. Hu F.Q., Jiang S.P., et al. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B Biointerfaces 2005, 45:167-173.
122. Hu F.Q., Zhang Y., et al. Nimodipine loaded lipid nanospheres prepared by solvent diffusion method in a drug saturated aqueous system. Int. J. Pharm. 2008, 348:146-152.
123. Hu L., Jia H., et al. Improvement of digoxin oral absorption in rabbits by incorporation into solid lipid nanoparticles. Pharmazie 2010, 65:110-113.
124. Hu L., Jia Y., et al. Preparation and characterization of solid lipid nanoparticles loaded with epirubicin for pulmonary delivery. Pharmazie 2010, 65:585-587.
125. Hu L., Xing Q., et al. Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles. AAPS PharmSciTech 2010, 11:582-587.
126. Hung O.R., Comeau L., Riley M.R., Tan S., Whynot S., Mezei M. Comparative topical anaesthesia of EMLA and liposome-encapsulated tetracaine. Can. J. Anaesth. 1997, 44:707-711.
127. Hussain N., Jani P.U., et al. Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat. Pharm. Res. 1997, 14:613-618.
128. Immordino M.L., Dosio F., Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed. 2006, 1:297-315.
129. Iscan Y., Wissing S.A., et al. Solid lipid nanoparticles (SLN) for topical drug delivery: incorporation of the lipophilic drugs N,N-diethyl-m-toluamide and vitamin K. Pharmazie 2005, 60:905-909.
130. Jain S.K., Chourasia M.K., et al. Solid lipid nanoparticles bearing flurbiprofen for transdermal delivery. Drug Deliv. 2005, 12:207-215.
131. Jee J.P., Lim S.J., et al. Stabilization of all-trans retinol by loading lipophilic antioxidants in solid lipid nanoparticles. Eur. J. Pharm. Biopharm. 2006, 63:134-139.
132. Jenning V., Gohla S.H. Encapsulation of retinoids in solid lipid nanoparticles (SLN). J. Microencapsul. 2001, 18:149-158.
133. Jenning V., Gysler A., et al. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur. J. Pharm. Biopharm. 2000, 49:211-218.
134. Jenning V., Schafer-Korting M., et al. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J. Control Rel. 2000, 66:115-126.
135. Jensen L.B., Magnussson E., et al. Corticosteroid solubility and lipid polarity control release from solid lipid nanoparticles. Int. J. Pharm. 2010, 390:53-60.
136. Jores K., Mehnert W., et al. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J. Control Rel. 2004, 95:217-227.
137. Jores K., Haberland A., et al. Solid lipid nanoparticles (SLN) and oil-loaded SLN studied by spectrofluorometry and Raman spectroscopy. Pharm. Res. 2005, 22:1887-1897.
138. Joshi M., Misra A.N. Pulmonary disposition of budesonide from liposomal dry powder inhaler. Methods Find. Exp. Clin. Pharmacol. 2001, 23:531-536.
139. Joshi M.D., Muller R.H. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm. 2009, 71:161-172.
140. Junping W., Maitani Y., Takayama K., Nagai T. In vivo evaluation of doxorubicin carried with long circulating and remote loading proliposome. Int. J. Pharm. 2000, 203:61-69.
141. Justo O.R., Moraes A.M. Incorporation of antibiotics in liposomes designed for tuberculosis therapy by inhalation. Drug Deliv. 2003, 10:201-207.
142. Kalam M.A., Sultana Y., et al. Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system. J. Drug Target 2010, 18:191-204.
143. Kassem M.A., Abdel Rahman A.A., et al. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int. J. Pharm. 2007, 340:126-133.
144. Kaur I.P., Kapila M., et al. Role of novel delivery systems in developing topical antioxidants as therapeutics to combat photoageing. Ageing Res. Rev. 2007, 6:271-288.
145. Kaur I.P., Bhandari R., et al. Potential of solid lipid nanoparticles in brain targeting. J. Control Rel. 2008, 127:97-109.
146. Kent J., Huiling M., Xuebing X., et al. Oxidative stability of liposomes composed of docosahexaenoic acid-containing phospholipids. J. Am. Oil Chem. Soc. 2007, 84:631-637.
147. Khoo S.M., Edwards G.A., et al. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. J. Pharm. Sci. 2001, 90:1599-1607.
148. Kikuchi A., Aoki Y., Sugayama S., et al. Development of novel cationic liposomes for efficient gene transfer into peritoneal disseminated tumor. Human Gene Ther. 1999, 10:947-955.
149. Killion J.J., Fidler I.J. Systemic targeting of liposome-encapsulated immunomodulators to marcrophages for treatment of cancer metastasis. Immunomethods 1994, 4:273-279.
150. Kim H.R., Kim I.K., et al. Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA. Mol. Pharm. 2008, 5:622-631.
151. Kim J.-K., Choi S.-H., Kim C.-O., Park J.-S., Ahn W.-S., Kim C.-K. Enhancement of polyethylene glycol (PEG)-modified cationic liposome-mediated gene deliveries: effects on serum stability and transfection efficiency. J. Pharm. Pharmacol. 2003, 55:453-460.
152. Kim S.T., Jang D.J., et al. Topical administration of cyclosporin A in a solid lipid nanoparticle formulation. Pharmazie 2009, 64:510-514.
153. Kirby C., Gregoriadis G. A simple procedure for preparing liposomes capable of high encapsulation efficiency under mild conditions. Liposomes technology 1984, 19-28. CRC Press:, Boca Raton, FL.
154. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipatic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990, 268:235-238.
155. Koshkina N.V., et al. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin. Cancer Res. 2000, 6:2876-2880.
156. Koshkina N.V., Golunski E., Roberts L.E., Gilbert B.E., Knight V. Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. J. Aerosol. Med. 2004, 17:7-14.
157. Kremer J.M.H., Esker M.W.J.V.D., Pathmamanoharan C., Wiersema P.H. Vesicles of variable diameter prepared by a modified injection method. Biochem. 1977, 16:3932-3935.
158. Kumar V.V., Chandrasekar D., et al. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics. Int. J. Pharm. 2007, 335:167-175.
159. Kuo J.H., Hwang R. Preparation of DNA dry powder for non-viral gene delivery by spray-freeze drying: effect of protective agents (polyethyleneimine and sugars) on the stability of DNA. J. Pharm. Pharmacol. 2004, 56:27-33.
160. Kuo Y.C., Lin S.C. Effect of glutamate on the electrical properties of cationic solid lipid nanoparticles containing stearylamine and dioctadecyldimethyl ammonium bromide. J. Phys. Chem. B 2008, 112:4454-4460.
161. Kuo Y.C., Chen H.H. Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles. Int. J. Pharm. 2009, 365:206-213.
162. Lasic D.D. Mechanisms of liposome formation. J. Liposome Res. 1995, 5:431-441.
163. Lasic D.D. Liposomes. Sci. Med. 1996, 3:34-43.
164. Law S.L., Huang K.J., Chiang C.H. Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption. J. Control Rel. 2000, 63:135-140.
165. Leventis R., Silvius J.R. Interactions of mammalian cells with lipid dispersions containing novel metabolizable cationic amphiphiles. Biochim. Biophys. Acta 1990, 1023:124-132.
166. Li H., Song J.H., Park J.S., Han K. Polyethylene glycol-coated liposomes for oral delivery of recombinant human epidermal growth factor. Int. J. Pharm. 2003, 258:11-19.
167. Li H., Zhao X., et al. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J. Control Rel. 2009, 133:238-244.
168. Li Y.Z., Sun X., et al. Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles. Pharm. Res. 2010, 27:1977-1986.
169. Lian T., Ho R.J.Y. Trends and developments in liposome drug delivery systems. J. Pharm. Sci. 2001, 90:667-680.
170. Lin H.H., Ko S.M., Hsu L.R., Tsai Y.H. The preparation of norfloxacin-loaded liposomes and their in-vitro evaluation in pig's eye. J. Pharm. Pharmacol. 1996, 48:801-805.
171. Lin Y.K., Huang Z.R., et al. Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int. J. Nanomed. 2010, 5:117-128.
172. Liu J., Gong T., et al. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization. Int. J. Pharm. 2007, 340:153-162.
173. Liu J., Hu W., et al. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int. J. Pharm. 2007, 328:191-195.
174. Liu J., Gong T., et al. Solid lipid nanoparticles for pulmonary delivery of insulin. Int. J. Pharm. 2008, 356:333-344.
175. Liu Z., Zhong Z., et al. Folate receptor mediated intracellular gene delivery using the charge changing solid lipid nanoparticles. Drug Deliv. 2009, 16:341-347.
176. Liu D., Ge Y., et al. Solid lipid nanoparticles for transdermal delivery of diclofenac sodium: preparation, characterization and in vitro studies. J. Microencapsul. 2010, 27:726-734.
177. Lo Y.L., Tsai J.C., Kuo J.H. Liposomes and disaccharides as carriers in spray-dried powder formulations of superoxide dismutase. J. Control Rel. 2004, 94:259-272.
178. Lu W., He L.C., et al. The use of solid lipid nanoparticles to target a lipophilic molecule to the liver after intravenous administration to mice. Int. J. Biol. Macromol. 2008, 43:320-324.
179. Lu X., Howard M.D., et al. Nanoparticles containing anti-inflammatory agents as chemotherapy adjuvants: optimization and in vitro characterization. AAPS J. 2008, 10:133-140.
180. Lu X., Howard M.D., et al. Nanoparticles containing anti-inflammatory agents as chemotherapy adjuvants II: role of plasma esterases in drug release. AAPS J. 2009, 11:120-122.
181. Luo Y., Chen D., et al. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J. Control Rel. 2006, 114:53-59.
182. Luo Q., Zhao J., et al. Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system. Int. J. Pharm. 2010, 403:185-191.
183. Lv Q., Yu A., et al. Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery. Int. J. Pharm. 2009, 372:191-198.
184. Ma P., Dong X., et al. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. J. Biomed. Nanotechnol 2009, 5:151-161.
185. Maa Y.F., Prestrelski S.J. Biopharmaceutical powders: particle formation and formulation considerations. Curr. Pharm. Biotechnol. 2000, 1:283-302.
186. Maa Y.F., Nguyen P.A., Sit K., Hsu C.C. Spray-drying performance of a bench-top spray dryer for protein aerosol powder preparation. Biotechnol. Bioeng. 1998, 60:301-309.
187. Maa Y.F., Nguyen P.A., Sweeney T., Shire S.J., Hsu C.C. Protein inhalation powders: spray drying vs spray freeze drying. Pharm. Res. 1999, 16:249-254.
188. Maeda H., Sawa T., Konno T. Mechanism of tumortargeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control Rel. 2001, 74:47-61.
189. Maghrabya G.M.E., Barryc B.W., Williamsd A.C. Liposomes and skin: from drug delivery to model membranes. Eur. J. Pharm. Sci. 2008, 34:203-222.
190. Maia C.S., Mehnert W., et al. Solid lipid nanoparticles as drug carriers for topical glucocorticoids. Int. J. Pharm. 2000, 196:165-167.
191. Maitani Y., Soeda H., Junping W., Takayama K. Modified ethanol injection method for liposomes containing β-sitosterol β-d-glucoside. J. Liposome Res. 2001, 11:115-125.
192. Malmsten M. Surfactants and Polymers in Drug Delivery 2002, 87-131. Marcel Dekker:, New York.
193. Manjunath K., Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Drug Target 2006, 14:632-645.
194. Mansour H.M., Hickey A.J. Raman characterization and chemical imaging of biocolloidal self-assemblies, drug delivery systems, and pulmonary inhalation aerosols: a review. AAPS PharmSciTech 2007, 8:E99.
195. Mansour H.M., Zografi G. The relationship between water vapor absorption and desorption by phospholipids and bilayer phase transitions. J. Pharm. Sci. 2007, 96:377-396.
196. Mansour H.M., Zografi G. Relationships between equilibrium spreading pressure and phase equilibria of phospholipid bilayers and monolayers at the air-water interface. Langmuir 2007, 23:3809-3819.
197. Mansour H.M., Wang D.-S., Chen C.-S., Zografi G. Comparison of bilayer and monolayer properties of phospholipid systems containing dipalmitoylphosphatidylglycerol and dipalmitoylphosphatidylinositol. Langmuir 2001, 17:6622-6632.
198. Mansour H.M., Damodaran S., Zografi G. Characterization of the in situ structural and interfacial properties of the cationic hydrophobic heteropolypeptide, kl4, in lung surfactant bilayer and monolayer models at the air-water interface: implications for pulmonary surfactant delivery. Mol. Pharmaceut. 2008, 5:681-695.
199. Mansour H.M., Rhee Y.S., Wu X. Nanomedicine in pulmonary delivery. Int. J. Nanomed. 2009, 4:299-319.
200. Martin F., Papahadjopoulos D. Irreversible coupling of immunoglobulin fragments to preformed vesicles. J. Biol. Chem. 1982, 257:286-288.
201. Martins S., Sarmento B., et al. Lipid-based colloidal carriers for peptide and protein delivery-liposomes versus lipid nanoparticles. Int. J. Nanomed. 2007, 2:595-607.
202. Mayer L.D., Hope M.J., Cullis P.R. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim. Biophys. Acta 1986, 858:161-168.
203. Mayhew E., Lazo R., Vail W.J., King J., Green A.M. Characterization of liposomes prepared using a microemulsifier. Biochim. Biophys. Acta 1984, 775:169-174.
204. Mehnert W., Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 2001, 47:165-196.
205. Mei Z., Chen H., et al. Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Eur. J. Pharm. Biopharm. 2003, 56:189-196.
206. Metselaar J.M., Mastrobattista E., Storm G. Liposomes for intravenous drug targeting: design and applications. Mini-Rev. Med. Chem. 2002, 2:319-329.
207. Metselaar J.M., Bruin P., DeBoer L.W.T., et al. A novel family of L-amino acid-based biodegradable polymerlipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. Bioconjugate Chem. 2003, 14:1156-1164.
208. Mezei M., Gulasekharam V. Liposomes-a selective drug delivery system for topical route of administration. 1. Lotion dosage form. Life Sci. 1980, 26:1473-1477.
209. Mezei M., Gulasekharam V. Liposomes-a selective drug delivery system for topical route of administration: gel dosage form. J. Pharm. Pharmacol. 1982, 34:473-474.
210. Mikhaylova M., Stasinopoulos I., Kato Y., Artemov D., Bhujwalla Z.M. Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA. Cancer Gene Ther. 2009, 16:217-226.
211. Mina A., Kanako Y., Kazuo M. Oxidative stability of polyunsaturated fatty acid in phaophatidylcholine liposomes. Biosci. Biotechnol. Biochem. 2002, 66:2573-2577.
212. Minato S., Iwanaga K., Kakemi M., Yamashita S., Oku N. Application of polyethyleneglycol (PEG)-modified liposomes for oral vaccine: effect of lipid dose on systemic and mucosal immunity. J. Control Rel. 2003, 89:189-197.
213. Misra A., Jinturkar K., Patel D., Lalani J., Chougule M. Recent advances in liposomal dry powder formulations: preparation and evaluation. Expert Opin. Drug Deliv. 2009, 6:71-89.
214. Morel S., Terreno E., et al. NMR relaxometric investigations of solid lipid nanoparticles (SLN) containing gadolinium(III) complexes. Eur. J. Pharm. Biopharm. 1998, 45:157-163.
215. Morille M., Passirani C., Vonarbourg A., Clavreul A., Benoit J.P. Progess in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomater. 2008, 29:3477-3496.
216. Mosen K., Backstrom K., Thalberg K. Particle formation and capture during spray drying of inhalable particles. Pharm. Dev. Technol. 2004, 9:409-418.
217. Muchow M., Maincent P., et al. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev. Ind. Pharm. 2008, 34:1394-1405.
218. Muller R.H., Heinemann S. Fat emulsions for parenteral nutrition. I: Evaluation of microscopic and laser light scattering methods for the determination of the physical stability. Clin. Nutr. 1992, 11:223-236.
219. Muller R.H., Mader K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50:161-177.
220. Muller R.H., Radtke M., et al. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 2002, 54(Suppl 1):S131-S155.
221. Muller R.H., Runge S., et al. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int. J. Pharm. 2006, 317:82-89.
222. Muller R.H., Petersen R.D., et al. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv. Drug Deliv. Rev. 2007, 59:522-530.
223. Muller R.H., Runge S.A., et al. Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation. Eur. J. Pharm. Biopharm. 2008, 68:535-544.
224. Mura P., Maestrelli F., Rodriguez L.M.G., Michelacci I., Ghelardini C., Rabasco A.M. Development, characterization and in vivo evaluation of benzocaine-loaded liposomes. Eur. J. Pharm. Biopharm. 2007, 67:86-95.
225. Muranishi S., Fujita T., et al. Potential for lymphatic targeting of peptides. J. Control Rel. 1997, 46:157-164.
226. Needham D., McIntosh T.J., Lasic D.D. Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. Biochim. Biophys. Acta 1992, 1108:40-48.
227. Newman A.W., Byrn S.R. Solid-state analysis of the active pharmaceutical ingredient in drug products. Drug Discov. Today 2003, 8:898-905.
228. Niven R.W. Delivery of biotherapeutics by inhalation aerosol. Crit. Rev. Ther. Drug Carrier Syst. 1995, 12:151-231.
229. Paliwal R., Rai S., et al. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomed. 2009, 5:184-191.
230. Pandey R., Khuller G.K. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinburgh, Scotland) 2005, 85:227-234.
231. Pandey R., Sharma S., et al. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis (Edinburgh, Scotland) 2005, 85:415-420.
232. Pandita D., Ahuja A., et al. Characterization and in vitro assessment of paclitaxel loaded lipid nanoparticles formulated using modified solvent injection technique. Pharmazie 2009, 64:301-310.
233. Panyam J., Labhasetwar V. Targeting intracellular targets. Curr. Drug Del. 2004, 1:235-247.
234. Pardeike J., Hommoss A., et al. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int. J. Pharm. 2009, 366:170-184.
235. Patel G., Chougule M., Singh M., Misra A. Nanoliposomal dry powder formulations. Meth. Enzymol. 2009, 464:167-191.
236. Patton J.S., Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nature Rev. Drug Disc. 2007, 6:67-74.
237. Payne N.I., Timmins P., Ambrose C.V., Ward M.D., Ridgway F. Proliposomes: a novel solution to an old problem. J. Pharm. Sci. 1986, 75:325-329.
238. Pedersen N., Hansen S., et al. Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands. Eur. J. Pharm. Biopharm. 2006, 62:155-162.
239. Pegi A., Julijana K., et al. The effect of lipophilicity of spin-labeled compounds on their distribution in solid lipid nanoparticle dispersions studied by electron paramagnetic resonance. J. Pharm. Sci. 2003, 92:58-66.
240. Pison U., Welte T., et al. Nanomedicine for respiratory diseases. Eur. J. Pharmacol. 2006, 533:341-350.
241. Planas M.E., Gonzalez P., Rodriguez L., Sanchez S., Cevc G. Noninvasive percutaneous induction of topical analgesia by a new type of drug carrier, and prolongation of local pain insensitivity by anesthetic liposomes. Anesth. Analg. 1992, 75:615-621.
242. Pleyer U., Lutz S., Jusko W.J., et al. Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. Invest. Ophthalmol. Vis. Sci. 1993, 34:2737-2742.
243. Pople P.V., Singh K.K. Development and evaluation of topical formulation containing solid lipid nanoparticles of vitamin A. AAPS PharmSciTech 2006, 7:91.
244. Porter C.J., Charman W.N. Intestinal lymphatic drug transport: an update. Adv. Drug Deliv. Rev. 2001, 50:61-80.
245. Rahman Z., Zidan A.S., et al. Non-destructive methods of characterization of risperidone solid lipid nanoparticles. Eur. J. Pharm. Biopharm. 2010, 76:127-137.
246. Rehman M., Shekunov B.Y., York P., et al. Optimisation of powders for pulmonary delivery using supercritical fluid technology. Eur. J. Pharm. Sci. 2004, 22:1-17.
247. Rhee Y.S., Mansour H.M. Nanopharmaceuticals I: nanocarrier systems in drug delivery. Int. J. Nanotechnol 2011, 8:84-114.
248. Rogers T., Johnston K., Williams R. Solution-based particle formation of pharmaceutical powders by supercritical or compressed Fluid CO2 and cryogenic spray-freezing technologies. Drug Dev. Ind. Pharm. 2001, 27:1003-1016.
249. Rudolph C., Schillinger U., et al. Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo. Pharm. Res. 2004, 21:1662-1669.
250. Saleki-Gerhardt A., Ahlneck C., Zografi G. Assessment of disorder in crystalline solids. Int. J. Pharm. 1994, 101:237-247.
251. Samad A., Sultana Y., Aqil M. Liposomal drug delivery systems: an update review. Curr.Drug Del. 2007, 4:297-305.
252. Sanjula B., Shah F.M., et al. Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. J. Drug Target 2009, 17:249-256.
253. Sanna V., Gavini E., et al. Solid lipid nanoparticles (SLN) as carriers for the topical delivery of econazole nitrate: in-vitro characterization, ex-vivo and in-vivo studies. J. Pharm. Pharmacol. 2007, 59:1057-1064.
254. Sarmento B., Martins S., et al. Oral insulin delivery by means of solid lipid nanoparticles. Int. J. Nanomed. 2007, 2:743-749.
255. Saupe A., Gordon K.C., et al. Structural investigations on nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers by cryo-field emission scanning electron microscopy and Raman spectroscopy. Int. J. Pharm. 2006, 314:56-62.
256. Schafer-Korting M., Mehnert W.G., et al. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv. Drug Deliv. Rev. 2007, 59:427-443.
257. Schneider T., Sachse A., Rossling G., Brandl M. Largescale production of liposomes of defined size by a new continuous high pressure extrusion device. Drug Dev. Ind. Pharm. 1994, 20:2787-2807.
258. Schneider T., Sacfse A., Robling G., Brandl M. Generation of contrast-carrying liposomes of defined size with a new continuous high pressure extrusion method. Int. J. Pharm. 1995, 119:1-12.
259. Schubert M.A., Muller-Goymann C.C. Solvent injection as a new approach for manufacturing lipid nanoparticles-evaluation of the method and process parameters. Eur. J. Pharm. Biopharm. 2003, 55:125-131.
260. Senior J.H. A review of controlling factors. Crit. Rev. Ther. Drug Carrier Syst 1987, 3:23-93.
261. Shah M., Pathak K. Development and statistical optimization of solid lipid nanoparticles of simvastatin by using 2(3) full-factorial design. AAPS PharmSciTech 2010, 11:489-496.
262. Shah S.P., Misra A. Development of liposomal Amphotericin B dry powder inhaler formulation. Drug Deliv. 2004, 11:247-253.
263. Shah S.P., Misra A. Liposomal amphotericin B dry powder inhaler: effect of fines on in vitro performance. Pharmazie 2004, 59:812-813.
264. Shah K.A., Date A.A., et al. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int. J. Pharm. 2007, 345:163-171.
265. Shahgaldian P., Quattrocchi L., et al. AFM imaging of calixarene based solid lipid nanoparticles in gel matrices. Eur. J. Pharm. Biopharm. 2003, 55:107-113.
266. Shekunov B.Y., Chattopadhyay P., Seitzinger J., Huff R. Nanoparticles of poorly water-soluble drugs prepared by supercritical fluid extraction of emulsions. Pharm. Res. 2006, 23:196-204.
267. Shi F., Wasungu L., Nomden A., et al. Interference of poly(ethylene glycol)-lipid analogues with cationic-lipid-mediated delivery of oligonucleotides; role of lipid exchangeability and non-lamellar transitions. Biochem. J. 2002, 366:333-341.
268. Siddiqui A., Patwardhan G.A., et al. Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles: in vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells. Int. J. Pharm. 2010, 400:251-259.
269. Siekmann B., Westesen K. Sub-micron sized parenteral carrier systems based on solid lipids. Pharm. Pharmacol. Lett. 1992, 1:123-126.
270. Siekmann B., Westesen K. Investigations on solid lipid nanoparticles prepared by precipitation in o/w emulsions. Eur. J. Pharm. Biopharm. 1996, 42:104-109.
271. Silva A.C., Santos D., et al. Minoxidil-loaded nanostructured lipid carriers (NLC): characterization and rheological behaviour of topical formulations. Pharmazie 2009, 64:177-182.
272. Simard P., Leroux J.C. pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leukemic cells. Int. J. Pharm. 2009, 381:86-96.
273. Singh R., Singh S., Lillard J.W. Jr. Past, present, and future technologies for oral delivery of therapeutic proteins. J. Pharm. Sci. 2008, 97:2497-2523.
274. Singh S., Dobhal A.K., et al. Formulation and evaluation of solid lipid nanoparticles of a water soluble drug: Zidovudine. Chem. Pharm. Bull. (Tokyo) 2010, 58:650-655.
275. Sjöström B., Bergenstahl B., et al. A method for the preparation of submicron particles of sparingly water-soluble drugs by precipitation in oil-in-water emulsions. II: Influence of the emulsifier, the solvent, and the drug substance. J. Pharm. Sci. 1993, 82:584-589.
276. Sjöström B., Kronberg B., et al. A method for the preparation of submicron particles of sparingly water-soluble drugs by precipitation in oil-in-water emulsions. I: Influence of emulsification and surfactant concentration. J. Pharm. Sci. 1993, 82:579-583.
277. Sjöström B., Westesen K., et al. Preparation of submicron drug particles in lecithin-stabilized o/w emulsions: II. Characterization of cholesteryl acetate particles. Int. J. Pharm. 1993, 94:89-101.
278. Sjöström B., Kaplun A., et al. Structures of nanoparticles prepared from oil-in-water emulsions. Pharm. Res. 1995, 12:39-48.
279. Song K.H., Chung S.J., Shim C.K. Preparation and evaluation of proliposomes containing salmon calcitonin. J. Control Rel. 2002, 84:27-37.
280. Souto E.B., Anselmi C., et al. Preparation and characterization of n-dodecyl-ferulate-loaded solid lipid nanoparticles (SLN). Int. J. Pharm. 2005, 295:261-268.
281. Stahl K., Claesson M., Lilliehorn P., Linden H., Backstrom K. The effect of process variables on the degradation and physical properties of spray dried insulin intended for inhalation. Int. J. Pharm. 2002, 233:227-237.
282. Stano P., Bufali S., Pisano C., et al. Novel camptothecin analogue (Gimatecan)-containing liposomes prepared by the ethanol injection method. J. Liposome Res. 2004, 14:87-109.
283. Steckel H., Thies J., Muller B.W. Micronizing of steroids for pulmonary delivery by supercritical carbon dioxide. Int. J. Pharm. 1997, 152:99-110.
284. Stevens P.J., Sekido M., et al. Synthesis and evaluation of a hematoporphyrin derivative in a folate receptor-targeted solid-lipid nanoparticle formulation. Anticancer Res. 2004, 24:161-165.
285. Storm G., Crommelin D.J.A. Liposomes: quo vadis?. PSTT 1998, 1:19-31.
286. Storm G., et al. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug Deliv. Rev. 1995, 17:31-48.
287. Sung J.C., Pulliam B.L., et al. Nanoparticles for drug delivery to the lungs. Trends in Biotechnol. 2007, 25:563-570.
288. Suresh G., Manjunath K., et al. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech 2007, 8:24.
289. Sweeney L., Wang Z., Loebenberg R., Wong J.P., Lange C.F., Finlay W. Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int. J. Pharm. 2005, 305:180-185.
290. Symon Z., et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 1999, 86:72-78.
291. Tabatt K., Sameti M., et al. Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle-mediated gene transfer. Eur. J. Pharm. Biopharm. 2004, 57:155-162.
292. Taira M.C., Chiaramoni N.S., Pecuch K.M., Alonso-Romanowski S. Stability of liposomal formulations in physiological conditions for oral drug delivery. Drug Deliv. 2004, 11:123-128.
293. Templeton N.S. Nonviral delivery for genomic therapy of cancer. World J. Surg. 2009, 33:685-697.
294. Ten Hagen T.L.M., Van Vianen W., Bakker-Woudenberg I.A.J.M. Modulation of nonspecific antimicrobial resistance of mice to Klebsiella Pneumoniae septicemia by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine and interferon-ã alone or combined. J. Infect. Dis. 1995, 171:385-392.
295. Tiyaboonchai W., Tungpradit W., et al. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int. J. Pharm. 2007, 337:299-306.
296. Tom J.W., Debenedetti P.G. Particle formation with supercritical fluids-a review. J. Aerosol. Sci. 1991, 22:555-584.
297. Torchilin V.P. Liposomes as targetable drug carriers. Crit. Rev. Ther. Drug Carrier Syst. 1985, 1:65-115.
298. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery 2005, 4:145-160.
299. Torchilin V.P., Trubetskoy V.S. Which polymers can make nanoparticulate drug carriers long-circulating?. Adv. Drug Deliv. Rev. 1995, 16:141-155.
300. Torchilin V.P., et al. Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. FASEB J. 1992, 6:2716-2719.
301. Torchilin V.P., et al. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim. Biophys. Acta 1994, 1195:11-20.
302. Torchilin V.P., et al. p-Nitrophenylcarbonyl-PEG-PEliposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim. Biophys. Acta 2001, 1511:397-411.
303. Trevaskis N.L., Charman W.N., et al. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv. Drug Deliv. Rev. 2008, 60:702-716.
304. Trotta M., Gallarate M., et al. Emulsions containing partially water-miscible solvents for the preparation of drug nanosuspensions. J. Control Rel. 2001, 76:119-128.
305. Trotta M., Debernardi F., et al. Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int. J. Pharm. 2003, 257:153-160.
306. Tsai M.J., Huang Y.B., et al. Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: Pharmacokinetic and behavioral evaluations. J. Pharm. Sci. 2010, 100:547-557.
307. Turanek J., Zaluska D., Něca J. Linkup of a fast protein liquid chromatography system with a stirred thermostated cell for sterile preparation of liposomes by the proliposome liposome method: application to encapsulation of antibiotics, synthetic peptide immunomodulators, and a photosensitizer. Analytical Biochem. 1997, 249:131-139.
308. Turanek J., Kasna A., Zaluska D., Neca J. Preparation of sterile liposomes by proliposome-liposome method. Methods Enzymol. 2003, 367:111-125.
309. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Draft Guidance for Industry: Liposome Drug Products - Chemistry, Manufacturing and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation. Office of Training and Communications, Division of Drug Information, HFD-240, Rockville, MD. (Internet) . http://www.fda.gov/cder/guidance/2191dft.pdf.
310. Ugazio E., Cavalli R., et al. Incorporation of cyclosporin A in solid lipid nanoparticles (SLN). Int. J. Pharm. 2002, 241:341-344.
311. Uhumwangho M.U., Okor R.S. Current trends in the production and biomedical applications of liposomes: a review. J. Biomed. Sci. 2005, 4:9-21.
312. Uner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Pharmazie 2006, 61:375-386.
313. Varia J.K., Dodiya S.S., et al. Cyclosporine A loaded solid lipid nanoparticles: optimization of formulation, process variable and characterization. Curr. Drug Deliv. 2008, 5:64-69.
314. Vasir J.K., Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv. Drug Deliv. Rev. 2007, 59:718-728.
315. Venkateswarlu V., Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J. Control Rel. 2004, 95:627-638.
316. Vidgren M.T., Vidgren P.A., Paronen T.P. Comparison of physical and inhalation properties of spray-dried and mechanically micronized disodium cromoglycate. Int. J. Pharm. 1987, 35:139-144.
317. Vighi E., Ruozi B., et al. Re-dispersible cationic solid lipid nanoparticles (SLNs) freeze-dried without cryoprotectors: characterization and ability to bind the pEGFP-plasmid. Eur. J. Pharm. Biopharm. 2007, 67:320-328.
318. Vighi E., Montanari M., et al. Nuclear localization of cationic solid lipid nanoparticles containing Protamine as transfection promoter. Eur. J. Pharm. Biopharm. 2010, 76:384-393.
319. Vighi E., Ruozi B., et al. pDNA condensation capacity and in vitro gene delivery properties of cationic solid lipid nanoparticles. Int. J. Pharm. 2010, 389:254-261.
320. Vyas S.P., Kannan M.E., Jain S., Mishra V., Singh P. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int. J. Pharm. 2004, 269:37-49.
321. Vyas S.P., Quraishi S., Gupta S., et al. Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages. Int. J. Pharm. 2005, 296:12-25.
322. Wagner A., Vorauer-Uhl K. Liposome technology for industrial purposes. J. Drug Deliv. 2011, 591325:1-9.
323. Wagner A., Vorauer-Uhl K., Kreismayr G., Katinger H. Enhanced protein loading into liposomes by the multiple crossflow injection technique. J. Liposome Res. 2002, 12:271-283.
324. Wagner A., Platzgummer M., Kreismayr G., et al. GMP production of liposomes-a new industrial approach. J. Liposome Res. 2006, 16:311-319.
325. Wagner A., Stiegler G., Vorauer-Uhl K., et al. One step membrane incorporation of viral antigens as a vaccine candidate against HIV. J. Liposome Res. 2007, 17:3-4.
326. Wang Y., Wu W. In situ evading of phagocytic uptake of stealth solid lipid nanoparticles by mouse peritoneal macrophages. Drug Deliv. 2006, 13:189-192.
327. Wang Y.J., Pearlman R. Formation, Characterization, and Stability of Protein Drugs. 1993, 159-199. Plenum Press:, New York.
328. Wang J.X., Sun X., et al. Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles. Eur. J. Pharm. Biopharm. 2002, 54:285-290.
329. Wang J.J., Liu K.S., et al. Skin permeation of buprenorphine and its ester prodrugs from lipid nanoparticles: lipid emulsion, nanostructured lipid carriers and solid lipid nanoparticles. J. Microencapsul. 2009, 26:734-747.
330. Wang T., Wang N., et al. Solvent injection-lyophilization of tert-butyl alcohol/water cosolvent systems for the preparation of drug-loaded solid lipid nanoparticles. Colloids Surf. B Biointer. 2010, 79:254-261.
331. Wartewig S., Neubert R.H. Pharmaceutical applications of Mid-IR and Raman spectroscopy. Adv. Drug Deliv. Rev. 2005, 57:1144-1170.
332. Wasungu L., Hoekstra D. Cationic lipids, lipoplexes and intracellular delivery of genes. J. Control Rel. 2006, 116:255-264.
333. Weiner N., Martin F., Riox M. Liposomes as drug delivery system. Drug Dev. Ind. Pharm. 1989, 15:1523-1554.
334. Wheeler C.J., Felgner P.L., Tsai Y.J., et al. A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:11454-11459.
335. White S., Bennett D.B., Cheu S., et al. EXUBERA: pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol. Ther. 2005, 7:896-906.
336. Wissing S.A., Muller R.H. Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin penetration. J. Control Rel. 2002, 81:225-233.
337. Wissing S.A., Muller R.H. Cosmetic applications for solid lipid nanoparticles (SLN). Int. J. Pharm. 2003, 254:65-68.
338. Wissing S.A., Muller R.H. The influence of solid lipid nanoparticles on skin hydration and viscoelasticity-in vivo study. Eur. J. Pharm. Biopharm. 2003, 56:67-72.
339. Wissing S.A., Kayser O., et al. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 2004, 56:1257-1272.
340. Wissing S.A., Muller R.H., et al. Structural characterization of Q10-loaded solid lipid nanoparticles by NMR spectroscopy. Pharm. Res. 2004, 21:400-405.
341. Wong H.L., Bendayan R., et al. Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J. Pharm. Sci. 2004, 93:1993-2008.
342. Wu L., Tang C., et al. Preparation and characterization of paclitaxel delivery system based on semi-solid lipid nanoparticles coated with poly (ethylene glycol). Pharmazie 2010, 65:493-499.
343. Wu Z.H., Ping Q.N., Wei Y., Lai J.M. Hypoglycemic efficacy of chitosan-coated insulin liposomes after oral administration in mice. Acta Pharmacol. Sin. 2004, 25:966-972.
344. Xiang Q.Y., Wang M.T., et al. Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles. Arch. Pharm. Res. 2007, 30:519-525.
345. Xing L., Dawei C., Liping X., Rongqing Z. Oral colonspecific drug delivery for bee venom peptide: development of a coated calcium alginate gel beads-entrapped liposome. J. Control Rel. 2003, 93:293-300.
346. Yamabe K., Kato Y., Onishi H., Machida Y. Potentiality of double liposomes containing salmon calcitonin as an oral dosage form. J. Control Rel. 2003, 89:429-436.
347. Yamada A., Taniguchi Y., Kawano K., Honda T., Hattori Y., Maitani Y. Design of folate-linked liposomal doxorubicin to its antitumor effect in mice. Clin. Cancer Res. 2008, 14:8161-8168.
348. Yang S., Zhu J., et al. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm. Res. 1999, 16:751-757.
349. Yang S.C., Lu L.F., et al. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control Rel. 1999, 59:299-307.
350. Yang W., Peters J.I., et al. Inhaled nanoparticles-A current review. Inter. J. Pharm. 2008, 356:239-247.
351. Yang W., Tam J., et al. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. Inter. J. Pharm. 2008, 361:177-188.
352. Yang L., Geng Y., et al. Enhancement the oral bioavailability of praziquantel by incorporation into solid lipid nanoparticles. Pharmazie 2009, 64:86-89.
353. Yan-yu X., Yun-mei S., Zhi-peng C., Qi-neng P. Preparation of silymarin proliposome: a new way to increase oral bioavailability of silymarin in beagle dogs. Int. J. Pharm. 2006, 319:162-168.
354. Ye J., Wang Q., et al. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. Int. J. Pharm. 2008, 352:273-279.
355. Yu B.T., Sun X., et al. Enhanced liver targeting by synthesis of N1-stearyl-5-Fu and incorporation into solid lipid nanoparticles. Arch. Pharm. Res. 2003, 26:1096-1101.
356. Yu Z., Garcia A.S., Johnston K.P., Williams R.O. Spray freezing into liquid nitrogen for highly stable protein nanostructured microparticles. Eur. J. Pharm. Biopharm. 2004, 58:529-537. 3rd.
357. Zalipsky S., Qazen M., Walker J.A., Mullah N., Quinn Y.P., Huang S.K. New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. Bioconjug. Chem. 1999, 10:703-707.
358. Zara G.P., Cavalli R., et al. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J. Drug Target 2002, 10:327-335.
359. Zhang X., Pan W., et al. Preparation of a dispersible PEGylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying. Chem. Pharm. Bull. (Tokyo) 2008, 56:1645-1650.
360. Zhao X.L., Yang C.R., et al. Preparation and characterization of nanostructured lipid carriers loaded traditional Chinese medicine, zedoary turmeric oil. Drug Dev. Ind. Pharm. 2010, 36:773-780.
361. Zhuang C.Y., Li N., et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int. J. Pharm. 2010, 394:179-185.
362. Zimmermann E., Souto E.B., et al. Physicochemical investigations on the structure of drug-free and drug-loaded solid lipid nanoparticles (SLN) by means of DSC and 1H NMR. Pharmazie 2005, 60:508-513.
363. zur Muhlen A., zur Muhlen E., et al. Atomic force microscopy studies of solid lipid nanoparticles. Pharm. Res. 1996, 13:1411-1416.